RECRUITING Phase 2 / Phase 3 ClinicalTrials.gov

RCT of Efficacy and Safety of CP003 on CFS/ME or Post COVID-19 Fatigue

Sponsor: The University of Hong Kong • ClinicalTrials.gov ID: NCT06739720

Registry updated: 2026-09-21

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

The goal of this clinical trial is to test if a Lingzhi supplement (CP003) helps people with chronic fatigue or post-COVID fatigue feel better. It will also check if the supplement is safe to use. The main questions it aims to answer are: Does the Lingzhi supplement reduce fatigue symptoms? Is it safe to take? How does it affect the body's immune system and inflammation? The investigators will compare people taking the Lingzhi supplement to those who do not receive any treatment (waitlist group) to see if it works. Participants will: * Take 5 capsules once daily for 6 weeks (or wait to start treatment if in waitlist group) * Visit the clinic 2 times for blood tests (before and after taking the supplement) * Complete questionnaires 3 times about their fatigue and quality of life (4 times participants in the waitlist group)

Interventions

LingZhi capsule (Drug)
Lingzhi-containing capsules (CP003) is a Chinese Medicine nutritional supplement manufactured by Chinese Pharm Co., Ltd, containing: wild red ganoderma extract, ganoderma spore powder (99.9% broken-wall), β-nicotinamide mononucleotide (NMN), wild yellow ganoderma extract, wild green ganoderma extract, wild purple ganoderma extract, wild white ganoderma extract, wild black ganoderma extract

Eligibility criteria

Inclusion Criteria: * Meet the Fukuda diagnostic definition of CFS/ME or have persisting fatigue after the infection of SARS-CoV-2 * Are able to complete a 6-week course of intervention; * Able to complete the online validated fatigue surveys. Exclusion Criteria: * Have participated in any type of complements or herbal medicine within the past six months; * Have serious medical conditions that might limit their participation in this intervention; * Diagnosed with acute inflammation; * Are pregnant or are planning a pregnancy in the next 3 months.

Conditions

Chronic Fatigue Syndrome (CFS) Post-COVID ME/CFS

Locations

Specialist Clinical Centre for Teaching and Research, School of Chinese Medicine, The University of Hong Kong — Hong Kong, Hong Kong

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment